Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Holding AG

http://www.roche.com

Latest From Roche Holding AG

Keytruda, Opdivo May Be Only Part B Drugs Chosen For Medicare Negotiation In First Applicable Year

In general, more Part D drugs will be eligible than Part B drugs in the early years of the program because Part D drugs have higher levels of spending and so will dominate the list of candidates. A new report sizes up the drugs that would qualify for Medicare Price negotiation in 2026-2028.

Reimbursement Medicare

Lilly’s Omvoh Among Nine New Drugs Securing EU Marketing Thumbs Up

A number of new drugs have taken a major step towards being approved for use in the EU after receiving the nod from the European Medicines Agency’s human medicines committee, the CHMP. Meanwhile, the marketing applications for three drugs have been withdrawn.

Europe Approvals

Roche Continues To Cast Its Collaborations Net Wide

The Swiss major gets around 3,000 proposals per year and has assembled a 120-strong team to sift through them and access the best science out there. Global head of pharma partnering James Sabry tells Scrip what Roche is looking for in a partner.

Deals Business Strategies

Ransomware Attacks: The State Of Play As Indian Firms Mount Defense

Pharma continues to be targeted by cyber criminals – the latest being India’s top-ranked company, Sun Pharma. Experts highlight some of the key vulnerabilities and why firms need to prioritize cyber resilience.

Commercial Cybersecurity
See All

Company Information

  • Industry
  • In Vitro Diagnostics
  • Pharmaceuticals
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Other Names / Subsidiaries
    • Adheron Therapeutics
    • Anadys Pharmaceuticals, Inc.
    • Ariosa Diagnostics
    • Arius Research, Inc.
    • Boehringer Mannheim
    • CAPP Medical
    • Chugai Pharmaceutical Co., Ltd.
    • Dutalys GmbH
    • Flatiron Health
    • Foundation Medicine
    • GenMark Diagnostics, Inc.
    • Genentech Inc.
    • GeneWEAVE BioSciences, Inc.
    • Genia Technologies, Inc.
    • GlycArt Biotechnology
    • Hoffmann-La Roche
    • Inflazome Ltd.
    • Ignyta, Inc. (RXDX) (Actagene Oncology, Inc
    • NexDx, Inc.)
    • Inception 5
    • InterMune, Inc.
    • Inflazome Ltd.
    • IQuum, Inc.
    • Jecure Therapeutics
    • Kapa Biosystems, Inc.
    • Marcadia Biotech, Inc.
    • Medingo Ltd.
    • Memory Pharmaceuticals Corporation
    • mtm laboratories AG
    • Piramed Pharma
    • Santaris Pharma A/S
    • Seragon Pharmaceuticals
    • Signature Diagnostics AG
    • Stratos Genomics
    • Syntex Corporation
    • Tanox, Inc.
    • Tensha Therapeutics, Trophos SA
    • Ventana Medical Systems, Inc.
    • Viewics, Inc.
UsernamePublicRestriction

Register